Welcome to our dedicated page for Bioatla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on Bioatla stock.
BioAtla, Inc. develops Conditionally Active Biologic (CAB) antibody therapeutics for solid-tumor cancers. News about BCAB centers on clinical and regulatory updates for its antibody-drug conjugate, T-cell engager and bispecific programs, including mecbotamab vedotin (Mec-V), ozuriftamab vedotin, evalstotug, BA3182 and CAB-Nectin4 programs.
Company updates also cover operating results, financing agreements, license milestones, cost-containment actions, strategic-review disclosures, Nasdaq listing matters, shareholder votes and capital-structure changes tied to BioAtla's common stock and preferred-stock authorizations.
BioAtla (NASDAQ: BCAB) will effect a 50-for-1 share consolidation effective April 6, 2026 at 12:01 a.m. ET, with trading on a split-adjusted basis expected at market open on April 6, 2026. The move aims to regain compliance with Nasdaq's $1.00 minimum bid requirement.
No fractional shares will be issued; holders entitled to fractions will receive cash based on the closing price at the Effective Time. Equity awards, option exercise prices and plan share pools will be proportionately adjusted. New CUSIP: 09077B203.
BioAtla (Nasdaq: BCAB) initiated a formal process to monetize assets and engaged Tungsten Advisors to evaluate strategic options, including asset sales, licenses, partnerships or other transactions. The company implemented a restructuring and workforce reductions to cut operating expenses and preserve capital.
Financial highlights: 2025 R&D $43.6M (vs $63.1M in 2024), 2025 G&A $17.7M (vs $21.8M), 2025 net loss $59.6M (vs $69.8M), and cash of $7.1M as of Dec 31, 2025. Pre‑paid Advance Agreements were fully converted to common stock as of March 2026.
BioAtla (NASDAQ: BCAB) announced that its Board has launched a formal review of strategic options to maximize shareholder value, including potential sales, licensing, partnerships or other transactions. The Company simultaneously is executing a restructuring to cut operating expenses, including a workforce reduction of about 70%, and retained Tungsten Advisors as exclusive strategic financial advisor.
BioAtla said there is no assurance the process will produce a transaction and it does not intend to provide updates unless the Board approves an action or disclosure becomes appropriate.
BioAtla (Nasdaq: BCAB) and GATC Health announced a $40 million SPV financing to advance ozuriftamab vedotin (Oz-V) into a registrational Phase 3 trial for 2L+ oropharyngeal squamous cell carcinoma (OPSCC).
BioAtla will receive an initial $5 million at closing and expects the remaining $35 million in Q1 2026; BioAtla will retain 65% ownership of Oz-V while Inversagen AI will hold 35%. BioAtla will lead Phase 3 execution with enrollment anticipated to begin in early 2026 and a data path toward potential accelerated approval in the US.
BioAtla (Nasdaq: BCAB) entered agreements providing flexible financing totaling up to $22.5 million to support operations while finalizing a strategic partnership. BioAtla received a $7.125 million gross cash advance under Pre-paid Advance Agreements for $7.5 million face value, which accrues 4% interest and may be repaid in cash or converted into common stock at the lower of $1.39 or 95% of the lowest daily VWAP during a specified look-back. Yorkville committed up to $15 million under a Standby Equity Purchase Agreement to buy common stock at a 3% discount over three years if the company exercises its option. Tungsten Advisors acted as placement agent.
BioAtla (Nasdaq: BCAB) reported Q3 2025 results and clinical updates on Nov 13, 2025. The company achieved FDA alignment on a planned randomized Phase 3 Oz-V trial in 2L+ OPSCC with dual primary endpoints (overall response rate and overall survival) and potential accelerated approval. BA3182 (CAB-EpCAM x CAB-CD3-TCE) dose escalation showed a confirmed partial response ongoing >6 months and a Phase 1 readout is expected in H1 2026. Mecbotamab vedotin (Mec-V) showed median OS 21.5 months in 44 evaluable soft tissue sarcoma patients. Q3 results: R&D $9.5M, G&A $4.2M, net loss $15.8M, cash $8.3M and a recent $2.0M milestone payment.
BioAtla (Nasdaq: BCAB) reported that mecbotamab vedotin (Mec-V), an AXL-targeting CAB ADC, achieved a median overall survival (OS) of 21.5 months in a 44-patient subset with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma, versus ~12 months with approved agents.
Data (cutoff March 25, 2025) show median OS 22.9 months in the combination arm and 18.4 months in monotherapy; 12-month OS rate 73%; disease control rate 52%; two partial responses reported. Safety was manageable with no treatment-related deaths; grade 3/4 neutropenia 21% and transaminase elevations 16%.
BioAtla (Nasdaq: BCAB) will announce its third quarter 2025 financial results and provide business highlights on Thursday, November 13, 2025. The company will host a conference call and webcast at 4:30 p.m. ET to discuss results for the quarter ended September 30, 2025. Investors can access the live webcast via the company website and dial in domestically at (800) 343-4136 or internationally at (203) 518-9843 using Conference ID BIOATLA.
The press release with financial results will be posted in News Releases prior to the call, and a replay will be available under Events & Presentations in the Investors section of the website.
BioAtla (NASDAQ: BCAB) will present a poster at the International Papillomavirus Society Conference in Bangkok (Oct 23–26, 2025) detailing mechanistic rationale and clinical data for its ADC ozuriftamab vedotin (Oz-V) targeting ROR2 in advanced HPV+ oropharyngeal squamous cell carcinoma (OPSCC). The poster, titled “Targeting HPV E6/E7 Upregulation of the Transmembrane Receptor Tyrosine Kinase ROR2 with the ADC Ozuriftamab Vedotin in Patients with Advanced HPV+ Oropharyngeal Squamous Cell Carcinoma,” will be presented on Oct 25, 2025 during E-Poster 02 (6:30–8:00 PM ICT). The presentation provides a molecular review of CAB-ROR2-ADC, discusses ROR2 expression linked to HPV infection, and highlights clinical data previously shown at medical congresses. Presentation materials will be posted in the company’s Publications section at www.bioatla.com after the session concludes.
BioAtla (Nasdaq: BCAB) reported preliminary Phase 1 results for BA3182, a dual‑conditionally binding EpCAM x CD3 bispecific T‑cell engager, presented at ESMO 2025 (Oct 19, 2025). In a 35‑patient, heavily pretreated cohort (median 3 prior lines), BA3182 showed a confirmed partial response (cPR) at 0.6 mg in intrahepatic cholangiocarcinoma with >6 months without progression and prolonged tumor control at doses ≥0.6 mg. Safety was manageable: only 2 cytokine release syndrome events and reversible, transient liver analyte elevations; dose escalation continues and the maximally tolerated dose is not yet defined.